

**Glaucoma Management in the 21st Century: Improving Care and Expanding Access**

**Saturday, February 3, 2024**

**[Conference Description:](https://attendee.gotowebinar.com/register/5429855044220934235%22%20CLICK%20HERE%20TO%20REGISTER%20FOR%20THE%20LIVESTREAMWith%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

[CLICK HERE TO REGISTER FOR THE LIVESTREAM](https://attendee.gotowebinar.com/register/5429855044220934235%22%20CLICK%20HERE%20TO%20REGISTER%20FOR%20THE%20LIVESTREAMWith%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

[With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.](https://attendee.gotowebinar.com/register/5429855044220934235%22%20CLICK%20HERE%20TO%20REGISTER%20FOR%20THE%20LIVESTREAMWith%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this 4.00 for a maximum of 4.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Nothing to disclose - 01/09/2024 |
| Reza Razeghinejad, MD | Faculty | Grant or research support-Olleyes|Grant or research support-Equinox (Relationship has ended) - 01/26/2024 |
| Cindy Zheng , MD | Faculty | Nothing to disclose - 01/05/2024 |
| Elizabeth Dale, MD | Faculty | Consulting Fee-Sight Sciences - 01/12/2024 |
| Jesse Richman, MD | Faculty | Consulting Fee-Alcon|Royalties or Patent Beneficiary-Visionology|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Visionology|Paid consultant-Allergan (Relationship has ended) - 01/07/2024 |
| Jason Flamendorf, MD | Faculty | Nothing to disclose - 01/14/2024 |
| Natasha Kolomeyer, MD | Faculty | Consulting Fee-Allergan (Relationship has ended)|Grant or research support-Allergan|Grant or research support-Guardion Health Services Inc|Grant or research support-Equinox|Grant or research support-Nicox|Grant or research support-Olleyes|Grant or research support-Santen Pharmaceuticals|Grant or research support-Glaukos Corporation|Grant or research support-Diopsys|Grant or research support-Aerie Pharmaceuticals - 01/07/2024 |
| Lauren Hock, MD | Faculty | Nothing to disclose - 12/12/2023 |
| Ethan C Heck, BM | Activity Coordinator | Nothing to disclose - 01/10/2024 |
| Tina Xia, MD | Faculty | Grant or research support-Allergan - 01/15/2024 |
| Shaunna Lee, MD | Activity Coordinator | Nothing to disclose - 10/05/2023 |
| Ping Huang, MD, PhD | Faculty | Nothing to disclose - 01/05/2024 |
| Dilru C Amarasekera, MD | Faculty | Nothing to disclose - 01/08/2024 |
| Joel S Schuman , MD | Faculty | Consulting Fee-Zeiss|Advisor-Opticient|Private Corp Stock-Opticient|Advisor-AEYE Health|Private Corp Stock-AEYE Health|Consulting Fee-Alcon|Consulting Fee-Broadwing|Private Corp Stock-Ocugenix|Advisor-Ocugenix|Consulting Fee-Perfuse|Grant or research support-Perfuse (Relationship has ended)|Consulting Fee-Ocular Therpeutics|Public Corp Stock-Ocular Therapeutix|Consulting Fee-Dompé  - 01/23/2024 |
| Michael Pro, MD | Faculty, Planner | Nothing to disclose - 01/08/2024 |

